Mike Moradi

🧬 This week's Austin Bio + Health Roundup highlights significant data trends, my stance on covering funding announcements, new partnerships, and action across the Texas Bio Triangle. 🧬 💰 Funding: The Way I Plan to Cover Funding Announcements You may have seen reports of a local Bio & Health startup’s funding round through an SEC report filing. While some outlets have covered this, my position is not to. I prefer to support our builders directly rather than trolling the filings for scoops. There is plenty of real investigative journalism that our city would be well served by if that is where they focused. Remember I am not a journalist and I am not the media. When the company is ready to announce their round officially, I’ll gladly shout it to the rooftops. 📊 Data Peter Walker at Carta reports that in 2017, Biopharma and Medical Devices captured just under 10% of all VC dollars. By 2023, this figure rose to 17.7%, and in Q1 2024, it reached 24%. The overarching tailwinds favor our sector and region with trends towards Bio & Health and the physical & digital intersection. Energy and hardware, two other sector blossoming in Central Texas, also saw similar share gains. 🤝 M&A and Partnerships Sensi.AI, a 24/7 senior care intelligence agent, is partnering with Caring Senior Service to deploy SensiAI’s platform in Caring’s 50 locations across the US. This partnership allows seniors a better opportunity to age gracefully in their homes. 🚩 Texas Bio Triangle BioMedSA is hosting an event called Women in Bioscience, Thursday June 20th. It’s designed to connect and empower women in the bioscience industry across Central Texas, and features Randi Brosterman Hutchens discussing "Building your Personal Board." Find the link to the event in the comments. Houston-based Lokum, a staffing solution to connect clinicians and clinical staff to health care facilities, has raised a $700K pre-seed round. Congrats Ayoade (Joy) Ademuyewo on the raise. What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

16

7 Comments

🧬 This week's Austin Bio & Health Roundup covers new funding, insightful data, expanding footprints, local innovators' thoughts, recognitions, & booming developments across the Texas Bio Triangle. 🧬 💰 Funding Thoughtful AI has raised a $20M Series led by Drive Capital led by Nick Solaro. With that funding Thoughtful launched AI agents focused on claims processing, patient eligibility verification, and other healthcare back office functions. Congratulations to Alex Zekoff and the entire team! Drive Capital's investment in Thoughtful parallels their expansion into Austin putting feet on the ground with new Seed General Manager Anish Zuté. I expect we'll be hearing about more investments from them soon. Modicus Prime raised $3.5M to prevent drug product quality failures in biomanufacturing. A great example of Austin funding Austin as Silverton Partners led the round. Congrats to Taylor Chartier and team! A reminder: You may have seen some media covering SEC filings and trying to scoop startups on their funding announcements. I only announce funding when the companies do as I am not a “journalist” and I'm here to catalyze & support the builders 📊 Data Peter Walker released new Carta data breaking down the sector diversity of funding since 2022 in top. In Austin, Healthtech ranked number 3 at 13%, behind SaaS at 42% and Fintech at 13% (likely a decimal difference). Note that Carta breaks Bio & Health into three subcategories (Healthtech, Pharma/Biotech, and Med Device). Where would the sector rank when combined? Peter, any comment? 🚀 Launches, Expansions, and Milestones Neuralink, the brain computer interface company founded by Elon Musk, is expanding its presence in Texas with a new 100,000+ facility, further solidifying our region's position as a key neurotech hub. Given the recent news about the relocations of X to Austin and SpaceX to Starbase, Texas; might we see an even larger presence (maybe even HQ) for Neuralink in the future? 💡 Insights from Local Builders and Innovators Jaleh Daie, PhD shared her thoughts in SynBioBeta on building a durable bioeconomy and what it will take to get there. 🏆 Recognition Kerry Rupp, partner at True Wealth Ventures, has been appointed to the @Ascension Seton Foundation Board. Having VCs on the hospital boards (including the Foundation) will help further connect them to the innovation ecosystem. 🚩 Texas Bio Triangle Houston-based Octagos Health | The Future of Digital Health raised a $43 million Series B to advance AI-driven cardiac device monitoring. Congrats to Shanti Bansal, M.D. and the whole team! MD Anderson and Rice University are joining forces to launch a cancer bioengineering collaborative, focused on speeding up the movement of innovations from the lab to the market. What’s Next?

42

12 Comments

🧬 This week's Austin Bio & Health Roundup features key insights from other regions, exciting funding news, major research advancements, and significant developments across the Texas Bio Triangle. 🧬 💡Insights from Other Regions & My 2 Cents Patrick Sisson in Bisnow reported on the Research and Development District in downtown San Diego, a 1.7M sqft multi-use life sciences project. Costing $915M, it has 0 signed tenants just months before opening. Don’t forget that the San Diego region is one of the world’s top Bio & Health clusters. The critical issue: "To this day, much of the life sciences real estate in San Diego tends to be more office park or campus-style sites that aren’t in walkable urban neighborhoods." So, what does this have to do with Austin? You need alignment between location, infrastructure, & sector. I am not convinced that 80%+ of Bio & Health companies work downtown. Keep this in mind when people pitch a downtown Austin Life Science Innovation district. 💰 Funding Workweek, a publishing platform for business professionals, closed a $12.5M Series A.  This is in the Roundup because their vertical, run by Blake Madden, focuses on healthcare. It’s also another case of Austin funding Austin as the round was led by Next Coast Ventures. Congrats Adam Ryan! Koda Health, a digital care coordination company for advance planning, raised its oversubscribed Seed+ round led by Austin’s own Ecliptic Capital. Super pumped for you Tatiana Fofanova, Ph.D.! 🔬 Research & Medical Advancements Eliah Overbey, Professor of BioAstronautics (what a cool era we live in) at Austin’s newest university, the University of Austin, published a series of studies in Nature on what space flight does to humans. Professor Overbey led a multi-institutional research team that obtained 3,000 samples from the SpaceX 2021 Inspiration 4 flight, resulting in a “10-fold increase in publicly available human space cell health data." 🏆 Recognition Christian Keil & Ryan M.’s BuildList, a viral database of critical tech companies, features numerous Austin companies including Paradromics Inc. & Harmonic Bionics, Inc. in Bio & Health. Way to go Matt Angle and Mark Hunter! 🚀 Launches, Expansions, and Milestones Wheel launched Horizon, their new AI virtual care platform with predictive care pathways and configurable, patient-centered care programs. Amazing work Michelle Davey! Keyspan is bringing their affordable biomarker testing and personalized coaching to Austin Simply Fit to enhance their fitness programs. Kudos Nate Taylor! 🏙️ Community Join the BrainCheck-Alzheimer’s Association brain health panel on June 20th, featuring Briaincheck CEO Kim Rodriguez. Link to the event in the comments. I’ll be attending & hope to see you there! 🚩 Texas Bio Triangle Solugen, a synthetic biology unicorn, secured a $214 million loan from the Energy Department to build a Bioforge, marking a significant step for Houston’s industrial bio sector. What’s Next?

31

12 Comments

Excellent way to spend 1 minute, 30 seconds. DSO shares via an embedded video in the article below how Modality.AI is making an impact with patients. It is wonderful to have NIH SEED as a partner on this journey. Relentless Venture Fund David "DSO" Suendermann-Oeft #Neurotech #AI #BIO2024 #precisionmedicine #clinicaltrials #healthtech #healthcare #digitalhealth

2

Why Physicians Should Consider Investing in HealthTech Venture Funds As a physician deeply entrenched in the world of healthcare, I've observed firsthand the transformative impact of technology on our industry. From telemedicine to AI-driven diagnostics, the pace of innovation is staggering—and it’s only accelerating. Today, I want to share why we, as physicians, should consider investing in HealthTech venture funds 👇 - Driving Innovation: By investing in HealthTech funds, we're not just placing capital; we're actively propelling the future of medicine. Our investment helps fund the technologies that could one day revolutionize patient care and our daily medical practices. - Insider Expertise: Who better to understand the potential of a new medical technology than those of us in the field? Our clinical experience enables us to assess the feasibility and potential impact of innovations, making us well-suited to make informed investment decisions. - Spreading Impact Beyond Practice: While we impact lives daily through direct patient care, investing in a HealthTech fund allows us to extend our influence by supporting solutions that reach a global patient base, potentially benefiting millions. - Financial Returns: HealthTech is one of the fastest-growing sectors, and investing in this area offers a valuable opportunity for substantial financial returns. Diversifying our portfolios beyond traditional stocks and real estate into venture funds can offer a unique balance of risk and reward. - Personal and Professional Growth: Engaging with the startup and tech ecosystem exposes us to new ideas and business strategies, broadening our horizons beyond clinical practice. This can lead to professional growth and networking opportunities that may not otherwise arise. I encourage my fellow healthcare professionals to look into HealthTech venture funds as a way to participate in the broader spectrum of healthcare innovation. Our expertise and capital can play a crucial role in shaping the future of the industry. ---- To join our vibrant community of 2,000+ healthtech experts and thought leaders, click the link in my profile bio.

19

🩺 Before the year comes to a close, we are excited to take a break from the AI hype and share our thoughts on one of the most compelling investment areas: healthcare. 🥼We’ve had the pleasure of working with the brilliant Dr. Swathi Varanasi-Diaz as part of our sector deep dive series during Laconia’s Venture Cooperative program. ✨ In our new article, Dr. Swathi takes a deeper look into the healthcare investment landscape and identifies opportunities for innovation and growth. It’s been a pleasure working with Dr. Swathi on the report and we look forward to hearing your thoughts! 🚀Laconia have been investing in the space since 2020 and we are excited by the venture scale investment opportunities in provider operations, care systems change, personalized care, to name a few, that will increase care delivery efficiency and in turn increase health access & results. As always, if you are a b2b founder building in the space, we’d love to hear from you. 🍵 Grab a cup of tea, and dive right in. We hope you enjoy the report as much as we did: https://lnkd.in/eygXiNnm CC: Jeffrey Silverman , David Arcara , Geri Kirilova 🤍

19

3 Comments

🚀 Meet Our Advisors! We are excited to highlight that Neil Littman, Founding Partner of Bioverge Ventures and Partner of Riverine Ventures, as one of the esteemed advisors in our #H7 accelerator program. 👉 We are open for application for the 2024 Cohort of H7 Healthcare Accelerator, powered by H7 BioCapital. Early Bird Applications are open until 💥 July 20th 💥! 🦄 Apply for the Program: https://shorturl.at/TfJdB 🦄 Apply to Become Advisor: https://lnkd.in/eSbGpX28  📅 Early Bird Deadline: July 20th, 2024 🎯 About H7 Accelerator Program: https://lnkd.in/g3ycA8eE ------- 🎯Get to know our top-tier accelerator advisor - Neil Littman "Neil Littman, M.S. is Founder & CEO of Bioverge Ventures, a venture capital firm exclusively dedicated to investing in #earlystage, #cuttingedge #healthcare companies. Bioverge’s investment thesis is focused on companies spanning the intersection of health + tech that are utilizing advances in technology to modernize healthcare, from bench-to-bedside." "Previously, Neil was Vice President of Business Development at Notable Labs, an oncology startup and Bioverge portfolio company, where he led the development of global corporate partnerships and contributed to the strategic vision of Notable as part of the Senior Leadership Team. Neil oversaw business development at Notable through the successful completion of the company’s $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets." 🌷Apply now to learn invaluable insights from Neil Littman get connected with our 100+ industrial leading experts, pitch to top #investors, and scale your #startup! 🥳 Once you're selected for #H7 accelerator cohort, you'll be part of the #H7 community for life. Expand your business and expand your network with access to a talented group of founders, investors, mentors, and industry leaders. #accelerator #venturecapital #fundraising #healthcare #lifesciences #biotech #drugdevelopment #artificialintelligence #medicaldevices #hospitals #clinicaltrials #oncology #research #startup #founders #precisionmedicine #commercialization #sales

33

3 Comments

Happy to jump back into another episode of the Innovation Wave podcast. On this episode, Bob McGriff and I discuss the current state of the life sciences ecosystem through the halfway point of 2024. We offer thoughts and analysis of what to expect for the remainder of the year. It's still a case of survive to '25'. #LifeSciences #Innovation #Healthcare #VentureCapital

24

4 Comments

The healthcare landscape is rapidly evolving, driven by advancements in technology and a deeper understanding of patient care. I had the pleasure of speaking with Ambar Bhattacharyya, Co-Managing Partner at Maverick Ventures, on the latest episode of The Full Ratchet. Ambar has partnered with numerous billion-dollar companies like hims & hers, Cityblock Health, Devoted Health, and ConcertAI. His unique journey from rural America to becoming a prominent figure in venture capital offers invaluable insights into the future of healthcare and technology. We discuss his investment strategy at Maverick Ventures, the megatrends shaping healthcare, the impact of AI on the industry, and the importance of integrated care. Ambar also shares his thoughts on the challenges and opportunities in healthcare investment, offering a comprehensive view of what lies ahead. Check out TFR Episode 438 to catch our conversation. You'll be glad you listened. Link to the full episode is in the comment section below.

117

8 Comments

How are the increased levels of venture capital and federal funding impacting the biotech industry, and what specific areas of research and... #venturecapital #veteranventures

7

Thank you to Endpoints News for great coverage today of Breakout Ventures portfolio company Immusoft's positive results for the first patient ever dosed with an engineered B cell therapy. The company held a webinar yesterday with KOLs (Paul Orchard, Paul Harmatz), patient advocates (Mark Dant) and our partners at CIRM (Abla Creasey). HIGHLIGHTS:  This was an MPS I adult patient, treated at the lowest dose. While a pediatric disease, this is the standard protocol. But means that expectations were low and safety was goal. The patient remained on standard of care Aldurazyme (ERT) but then took a holiday at 8 months. The treatment required 𝙉𝙊 𝙥𝙧𝙚𝙘𝙤𝙣𝙙𝙞𝙩𝙞𝙤𝙣𝙞𝙣𝙜/ 𝙞𝙢𝙢𝙪𝙣𝙤𝙨𝙪𝙥𝙥𝙧𝙚𝙨𝙨𝙞𝙤𝙣. So even at dosing, we knew this patient would experience none of the adverse events associated with the toxicity of other treatments and did not have to spend the associated time in the hospital. Since the patient was dosed November 2023:  - 𝙏𝙝𝙚𝙧𝙚 𝙝𝙖𝙫𝙚 𝙗𝙚𝙚𝙣 𝙣𝙤 𝙖𝙙𝙫𝙚𝙧𝙨𝙚 𝙚𝙫𝙚𝙣𝙩𝙨  - confirming the safety profile - 𝙐𝙧𝙞𝙣𝙚 𝙂𝘼𝙂𝙨 𝙛𝙚𝙡𝙡 𝙞𝙣𝙩𝙤 𝙩𝙝𝙚 𝙣𝙤𝙧𝙢𝙖𝙡/𝙝𝙚𝙖𝙡𝙩𝙝𝙮 𝙧𝙖𝙣𝙜𝙚 𝙗𝙚𝙩𝙬𝙚𝙚𝙣 3-8 𝙢𝙤𝙣𝙩𝙝𝙨 after treatment. For context, in Aldurazyme’s clinical trial, none of the patients reached normal urinary GAG levels.  - 𝙃𝙚𝙥𝙖𝙧𝙞𝙣 𝙨𝙪𝙡𝙛𝙖𝙩𝙚 𝙞𝙣 𝙩𝙝𝙚 𝘾𝙎𝙁 𝙬𝙖𝙨 𝙙𝙤𝙬𝙣 25% 𝙖𝙩 6 𝙢𝙤𝙣𝙩𝙝𝙨, noting that the FDA has used this as an acceptable surrogate endpoint in MPS.  - 𝙏𝙝𝙚𝙧𝙚 𝙬𝙚𝙧𝙚 𝙨𝙪𝙧𝙥𝙧𝙞𝙨𝙞𝙣𝙜 𝙛𝙪𝙣𝙘𝙩𝙞𝙤𝙣𝙖𝙡 𝙞𝙢𝙥𝙧𝙤𝙫𝙚𝙢𝙚𝙣𝙩𝙨. These are adult patients, who are often struggling with the stiffness and lack of mobility that happens as the disease progresses. The patient saw a 30% 𝙞𝙢𝙥𝙧𝙤𝙫𝙚𝙢𝙚𝙣𝙩 𝙞𝙣 𝙖 6 𝙢𝙞𝙣𝙪𝙩𝙚 𝙬𝙖𝙡𝙠 𝙩𝙚𝙨𝙩 𝙖𝙣𝙙 𝙖𝙣 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚𝙙 𝙧𝙖𝙣𝙜𝙚 𝙤𝙛 𝙨𝙝𝙤𝙪𝙡𝙙𝙚𝙧 𝙢𝙤𝙩𝙞𝙤𝙣 𝙖𝙩 6 𝙢𝙤𝙣𝙩𝙝𝙨. Truly rewarding to see this sort of outcome in a patient. We are thrilled for what this could mean for all MPS I patients and the potential of b cells as therapy. Excited for this next phase for Immusoft and always happy to connect those of you who have been following the story directly to the company. 

75

3 Comments

As physicians, we are committed to improving patient care through clinical excellence. However, there's an often-overlooked avenue where our expertise can significantly impact healthcare innovation: serving as medical advisors for startups. Here are a few reasons why I believe we should engage with the entrepreneurial community 👇 1️⃣ Driving Innovation Forward: Startups are at the forefront of medical technology and services. By contributing our clinical expertise, we can guide these companies to develop solutions that are not only innovative but also practical and patient-centered. 2️⃣ Broadening Impact: While our primary influence is within the confines of our practices or hospitals, working with startups allows us to extend our impact globally. Technologies we help develop could benefit patients worldwide, many of whom could never visit us in person. 3️⃣ Learning and Growth: Engaging with startups exposes us to the latest technologies and business strategies, enriching our understanding beyond the medical field. This cross-disciplinary knowledge can enhance our own practices and the way we approach patient care. 4️⃣ Professional Networking: Collaborating with entrepreneurs and other tech innovators can open new doors. These connections can lead to other advisory roles, speaking opportunities, and even advancements in our own careers. 5️⃣ Financial Opportunities: Often, advising roles come with financial compensation, including equity options. These can provide significant financial benefits, particularly if the startup succeeds. 6️⃣ I urge my fellow clinicians to consider stepping into the role of a medical advisor. Our insights are invaluable, and our participation can be the key differentiator in the success of health-focused innovations. ---- Join our vibrant community of 2,000+ healthtech experts and thought leaders. Comment below or DM me, and I’ll provide you with an invitation to our fast-growing network. 📩

50

9 Comments

In addition to investments in tech and biotech companies, Apeiron Investment Group invests in companies that are going to help people make the most of their leisure time – as we believe that over the coming decades, thanks to AI and other tech innovations, this is something we will all have in abundance.   This year alone, in Apeiron’s “Experiences, Hospitality & Happiness” division we have launched Chiron Sports Group, a sports growth equity asset manager - and I became Co-Founder of the Enhanced Games, which has already triggered a seismic shift in the sector. Sport is a super exciting space to be in - and stands to generate solid returns, too.    Region-wise, the Middle East is a key focus area for Apeiron. And in a perfect overlap, the Middle East is actually one of the regions where the most is happening with regards to sport. From our base in Abu Dhabi, we’re building momentum in the region and have several major projects in motion - all being overseen by my team on the ground there, co-led by Philipp Schreiber and Salvatore Lavallo.    Philipp, who relocated to the UAE in April this year, and Salvatore, who made #UAE his home years ago, have made huge progress building our vision for the region and especially Philipp is personally passionate about sports. He wrote a really comprehensive overview of the sports landscape in the region - summarising progress so far and what’s coming up as countries like the UAE, #SaudiArabia and #Qatar invest in diversifying their economies. Check it out here: https://lnkd.in/ettTVxVD

46

1 Comment

🧬 This week's Austin Bio + Health Roundup has acquisitions, funding, leader’s insights on national healthcare news, critical new infrastructure, and developments from across the Texas Bio Triangle. 🧬 🤝 M&A and Partnerships Subjectwell, a patient access marketplace connecting patients to clinical trials and treatments, was acquired by Windrose Health Investors.  This acquisition will also provide Subjectwell with additional capital for its next growth phase. 💰 Funding Thoughtful Automation, an AI company specializing in revenue-cycle management tools for healthcare providers, has announced its move to Austin and has secured $12.5M in funding. Congrats and welcome to Central Texas! 💡 Insights from Local Builders and Innovators Michelle Davey, Founder and CEO of Wheel, provided her commentary to FierceHealthcare on the recent exits from the virtual care market by major players Walmart and Optum. Michelle said, “It's not just about being big—it's about the platform that drives the care delivery itself - and how it's purpose-built to scale to mass adoption and repeat utilization." 🏗️ Infrastructure Dell Med is launching a Center for Rare Diseases, focusing on cutting-edge research and therapies. This initiative will support advances in diagnostics and boost awareness, providing critical assistance for patients and families dealing with rare conditions. 🚀 Launches, Expansions, and Milestones The co-founder of artist collaborative Meow Wolf is leaving to launch a new $15M wellness and spa experience in Austin. They are branding it as the “world’s first neuroscience-enabled spa,” bringing a new element to the Austin’s strength at the convergence of bio, health, and tech. 🚩 Texas Bio Triangle First Bight Ventures’ industrial biology accelerator, BioWell, is now seeking its first cohort of 10 companies, with applications due by May 15. The STRONG STAR Consortium has secured $17 million in DoD funding to address brain injuries, PTSD, and related conditions, which will launch 8 programs spanning detection, prevention, and treatment. As always, the news is as varied and dynamic as our region, let’s keep it up! What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

12

1 Comment

🧬 This week's Austin Bio & Health Roundup highlights new funding, intriguing data, and major commercial & scientific milestones 🧬 💰 Funding Hello Patient, building Gen-AI phone agents for healthcare providers, came out of stealth with a $6.3M seed raise. Congrats Alex Cohen! And it’s Austin funding Austin, with 8VC a key part of the round. Aspira Women's Health, focused on non-invasive AI-powered diagnostics, was awarded a $10M grant from ARPA-H to advance their blood test for endometriosis. Well done, Nicole Sandford, Sandy Milligan, MD JD & team. Maxwell Biosciences, a synthetic small molecule drug platform, received ~$3M from the Medical Technology Enterprise Consortium (MTEC) to find assets that will prevent wound infection on the battlefield. Fantastic work, Joshua McClure & team. Reminder: I don’t cover SEC filings. When the builders themselves announce, I’ll shout it from the rooftops! 📊 Data Clutch VC released its Texas Seed Funding Update (YTD Q3): YTD 387 seed rounds raised for a total $636M. Though deal counts are down QoQ, capital invested has trended upward, making this the highest quarter since Q1 2023. Health was the second largest sector with 27% of all capital raised so far this year, up from 16% during the same time frame last year. Great data & insights Rajiv Bala, Steve Coffey, and Caitlin McHugh. 🤝 M&A and Partnerships Lumos Pharma entered a merger agreement with Double Point Ventures, going private at a $38M valuation. 🚀 Launches, Expansions, Milestones, and Wins Oracle Health announced updates to its Data Intelligence platform, with enhancements to Clinical, Analytics, and Care Coordination products. 🤠 Texas Bio Triangle Houston-based Coya Therapeutics, Inc. shared positive results from a double-blind study of low-dose interleukin-2 (LD-IL-2) in Alzheimer’s, showing the therapy is safe and well tolerated with promising trends toward cognitive improvement. Amazing Howard Berman, PhD, Arun Swaminathan, and the rest of the team. Dallas-based Stone Mountain Ventures closed a $5M Fund II focused on health & AI. Fund I included Austin Bio & Health startups Legion Health and MDisrupt. Congratulations, John Diaz and keep looking at Austin for new opportunities! Quick Note: Some items this week actually happened last week, apologies if I missed them! Please tag or message me for future announcements so I can make sure to include them. What’s Next?

43

7 Comments

🧬 This week's Austin Bio + Health Roundup brings exciting funding announcements, important community events, accolades, partnerships, and milestones from across the Texas Bio Triangle. 🧬 💰 Funding Humanaut Health has secured an $8.7M seed round to bring access to health optimization and longevity to the general population. It's Austin funding Austin, as Midnight Venture Partners joined the round. Don't miss my short interview with Co-founder and CEO Jim Donnelly below! Optmycare, an AI platform in healthcare & risk management, raised a $3 million in Series A funding, led by Austin's own LiveOak Ventures, to accelerate its growth and build out its technology. 🏙️ Community Mark your calendars for the Nucleate Texas Final Pitch Showcase on May 17th. Catch the final pitches from 1pm to 5pm at Highpoint 2222, and discover what's next in platform discoveries, diagnostics, and therapeutics. 🏆 Recognition BrainCheck, a brain health diagnostic and tools company, received the Care Management Innovation Award at the 8th annual MedTech Breakthrough Awards. Congratulations Kim Rodriguez and the entire team for the well-deserved recognition of your work.   🤝 M&A and Partnerships Babson Diagnostics has announced a new partnership with Cynergy Wellness LLC, to provide clinician oversight for Babson’s customer-initiated BetterWay blood tests. One more step in providing access to this novel technology. Congrats David Stein, Eric Olson and the rest of the Babson team. 🚩 Texas Bio Triangle San Antonio-based Hera Biotech has released promising interim results for their groundbreaking endometriosis treatment. The data showed 92% sensitivity, 95% specificity, and 94% overall accuracy compared to histopathology. Congrats Somer Baburek, MBA on this important step in the development of a greatly needed diagnostic. This week underscores breadth and depth of sector. Let's keep the momentum going! What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

116

10 Comments

It was wonderful to be in conversation with Madison Mills of Yahoo Finance at their annual Invest conference earlier this week. We covered everything from the venture outlook for 2025, impact of elections on women's health investing and innovation, and more. Full clip and summary below 👇 https://lnkd.in/gS67sc2Y

94

6 Comments

While the best startups are doing well, even in this tough venture capital market, others are struggling to raise new funding. If they can’t raise and haven’t become self-sustaining businesses, their best bet is to get acquired, even if it’s for a fraction of their last valuation. The alternative would be to run out of money and shut down.  https://lnkd.in/eGH64we5 Stay curious, stay informed, and stay tuned to OniX OnPoint! Subscribe to the OniX OnPoint Newsletter to stay updated on the latest biomedical innovations. https://lnkd.in/edUVWht9

2